Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates ... Industry leaders, including Pfizer, F. Hoffmann-La Roche, Astellas Pharma Inc., GSK, and AstraZeneca among others ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

Having already acquired UK-based Cambridge Antibody Technology in 2006 ... After rejecting Pfizer, AstraZeneca continued with its own M&A ambitions, and in the following years the company saw ...

Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market ... Industry leaders, including Pfizer, F. Hoffmann-La Roche, Astellas Pharma Inc., GSK, and AstraZeneca among others are ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. World revenue ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

The list of 36 drugs, which are exempt from basic customs duty, includes many expensive and imported medicines that can ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...